ALK-positive large B-cell lymphoma presenting in the nasal cavity with CLTC::ALK fusion: a case report of alectinib-integrated therapy followed by autologous hematopoietic stem cell transplantation.

Qiong Yi, Xiuwen Chen, Lulu Zhang

Abstract readCase Reports

In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qiong YiDepartment of Pathology and Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.

Xiuwen ChenDepartment of Pathology and Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.

Lulu ZhangDepartment of Pathology and Department of Hematology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is a rare and aggressive lymphoma for which no standard frontline treatment has been established. Presentation in the nasal cavity is particularly uncommon. We report the case of a 39-year-old man who presented with progressive left-sided nasal obstruction, epistaxis, and bilateral cervical lymphadenopathy. Imaging revealed a left sinonasal/nasopharyngeal mass, bilateral cervical lymphadenopathy, diffuse skeletal hypermetabolism, markedly elevated lactate dehydrogenase, and focal bone marrow involvement. Histopathologic examination showed a plasmablastic neoplasm with strong granular cytoplasmic ALK expression. The tumor cells were positive for CD138, MUM1, EMA, and kappa light chain, but negative for CD20, CD19, CD79a, CD3, CD30, CD56, and EBER. Fluorescence

Indexed as

alectinibALK-positive large B-cell lymphomaautologous hematopoietic stem cell transplantationCLTC::ALK fusionnasal cavitytargeted therapy

Identifiers

PMID42444814

DOI10.3389/fonc.2026.1876454

PMCPMC13357180

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.